z-logo
open-access-imgOpen Access
Circular RNA circRNA_101996 promoted cervical cancer development by regulating miR ‐1236‐3p/ TRIM37 axis
Author(s) -
Song TieFang,
Xu AiLi,
Chen XiuHui,
Gao JiaYin,
Gao Fei,
Kong XianChao
Publication year - 2021
Publication title -
the kaohsiung journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.439
H-Index - 36
eISSN - 2410-8650
pISSN - 1607-551X
DOI - 10.1002/kjm2.12378
Subject(s) - gene knockdown , medicine , cancer research , circular rna , cervical cancer , microrna , small hairpin rna , cell growth , metastasis , suppressor , carcinogenesis , bioinformatics , cancer , biology , gene , biochemistry
Circular RNAs (circRNAs) appear to be significant modulators in various physiological processes. Recently, it is found that circRNA_101996 exerts important roles in various cancers. Our previous studies showed that circRNA_101996 promoted cervical cancer growth and metastasis by regulating miR‐8075/TPX2. However, the potential regulatory role of circRNA_101996 in cervical cancer still needs further investigation. Our results in this study suggested that circRNA_101996 was over‐expressed in cervical cancer patients. circRNA_101996 up‐regulation remarkably assisted cell proliferation, cell cycle progression, and cell migration in cervical cancer, while circRNA_101996 knockdown exerted the inverse effects. The molecular investigations indicated that circRNA_101996 could increase the expression level of miR‐1236‐3p, tripartite motif‐containing 37 (TRIM37), through binding to miR‐1236‐3p and reducing its expression. Moreover, in vivo results demonstrated that circRNA_101996 shRNA can function as a tumor suppressor through down‐regulating TRIM37 in cervical cancer. In conclusion, our data indicated that circRNA_101996/miR‐1236‐3p/TRIM37 axis accelerated cervical cancer development, providing novel insights into cervical cancer diagnosis and treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here